1. Signaling Pathways
  2. Antibody-drug Conjugate/ADC Related
  3. Drug-Linker Conjugates for ADC
  4. Auristatin Isoform

Auristatin

 

Auristatin Related Products (47):

Cat. No. Product Name Effect Purity
  • HY-15575
    VcMMAE
    99.91%
    VcMMAE (mc-vc-PAB-MMAE) is a drug-linker conjugate for ADC with potent antitumor activity by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the lysosomally cleavable dipeptide, valine-citrulline (vc).
  • HY-15578
    McMMAF
    99.58%
    McMMAF is a protective group (maleimidocaproyl)-conjugated MMAF, which is a potent tubulin polymerization inhibitor.
  • HY-112786
    MC-Val-Cit-PAB-MMAF
    98.05%
    MC-Val-Cit-PAB-MMAF (Vc-MMAF) is a drug-linker conjugate for ADC by using the tubulin inhibitor, MMAF, linked via cathepsin cleavable MC-Val-Cit-PAB.
  • HY-100374
    Val-Cit-PAB-MMAE
    99.83%
    Val-Cit-PAB-MMAE is a drug-linker conjugate for ADC.
  • HY-15741
    Mc-MMAE
    Mc-MMAE is a protective group (maleimidocaproyl)-conjugated monomethyl auristatin E (MMAE), which is a potent tubulin inhibitor.
  • HY-147239
    MC-VA-PABC-MMAE
    99.88%
    MC-VA-PABC-MMAE is a drug-linker conjugate for ADC.
  • HY-145989A
    Aminobenzenesulfonic auristatin E TFA
    99.39%
    Aminobenzenesulfonic auristatin E TFA is a drug-linker conjugate for ADC.
  • HY-44177
    Val-Cit-PAB-MMAF sodium
    Val-Cit-PAB-MMAF sodium is a drug-linker conjugate for ADC.
  • HY-100566
    SuO-Val-Cit-PAB-MMAE
    98.75%
    SuO-Val-Cit-PAB-MMAE is a drug-linker conjugate for ADC by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the peptide SuO-Val-Cit-PAB.
  • HY-111012
    DBCO-(PEG)3-VC-PAB-MMAE
    Chemical
    DBCO-(PEG)3-VC-PAB-MMAE is a drug-linker conjugate for ADC.
  • HY-128955
    MC-VC-PABC-Aur0101
    98.87%
    MC-VC-PABC-Aur0101 is a drug-linker conjugate for ADC with potent antitumor activity by using Aur0101 (an auristatin microtubule inhibitor), linked via the ADC linker MC-VC-PABC.
  • HY-131056
    Gly3-VC-PAB-MMAE
    99.20%
    Gly3-VC-PAB-MMAE consists a cleavable ADC linker (Gly3-VC-PAB) and a potent tubulin inhibitor (MMAE).
  • HY-100567
    MAL-di-EG-Val-Cit-PAB-MMAE
    98.04%
    MAL-di-EG-Val-Cit-PAB-MMAE consists the ADCs linker (MAL-di-EG-Val-Cit-PAB) and potent tubulin inhibitor (MMAE).
  • HY-126681
    SC-VC-PAB-MMAE
    SC-VC-PAB-MMAE is a drug-linker conjugate for ADC with potent antitumor activity by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the cleavable linker SC-VC-PAB.
  • HY-100874
    N3-PEG3-vc-PAB-MMAE
    98.79%
    N3-PEG3-vc-PAB-MMAE is a synthesized drug-linker conjugate for ADC that incorporates the MMAE (a tubulin inhibitor ) and 3-unit PEG linker.
  • HY-128968
    PEG4-aminooxy-MMAF
    PEG4-aminooxy-MMAF is a drug-linker conjugate for ADC with potent antitumor activity by using the potent antitubulin agent MMAF, linked via the noncleavable PEG4.
  • HY-135660
    MMAE-SMCC
    MMAE-SMCC is a drug-linker conjugate for ADC.
  • HY-130989
    SuO-Glu-Val-Cit-PAB-MMAE
    98.74%
    SuO-Glu-Val-Cit-PAB-MMAE consists a cleavable ADC linker (SuO-Glu-Val-Cit-PAB) and a potent tubulin inhibitor (MMAE).
  • HY-128711
    MAL-di-EG-Val-Cit-PAB-MMAF
    98.56%
    MAL-di-EG-Val-Cit-PAB-MMAF consists the ADCs linker (MAL-di-EG-Val-Cit-PAB) and potent tubulin polymerization blocker (MMAF, Monomethyl auristatin F).
  • HY-133492
    DBCO-PEG4-MMAF
    DBCO-PEG4-MMAF is a drug-linker conjugate for ADC with potent antitumor activity by using the tubulin polymerization inhibitor, MMAF, linked via the cleavable linker DBCO-PEG4.